405939-39-1

Usage

Uses

Used in Pharmaceutical Synthesis:
N-BOC-2-AMINO-5-BROMOTHIAZOLE is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure and reactivity make it a promising candidate for the development of new drugs with improved therapeutic properties.
Used in Agrochemical Synthesis:
In the agrochemical industry, N-BOC-2-AMINO-5-BROMOTHIAZOLE serves as a building block for the creation of novel agrochemicals. Its incorporation into these compounds can lead to enhanced pest control and crop protection.
Used in Organic Synthesis:
N-BOC-2-AMINO-5-BROMOTHIAZOLE is utilized as a versatile building block in organic synthesis. Its presence in various chemical reactions allows for the formation of a wide range of organic compounds with diverse applications.
Used in Medicinal Chemistry Research:
N-BOC-2-AMINO-5-BROMOTHIAZOLE is employed in medicinal chemistry research to explore its potential as a precursor for the development of new therapeutic agents. Its unique properties and reactivity make it an attractive candidate for further investigation and application in drug discovery processes.

InChI:InChI=1/C8H11BrN2O2S/c1-8(2,3)13-7(12)11-6-10-4-5(9)14-6/h4H,1-3H3,(H,10,11,12)

Upstream product

• 957346-62-2 5-bromo-1,3-thiazole-2-carboxylic acid 
• 75-65-0 tert-butyl alcohol 
• 3034-22-8 5-bromo-2-aminothiazole 
• 4248-19-5 tert-butyl carbazate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 61296-22-8 5-bromothiazol-2-amine hydrobromide 
• 170961-15-6 tert-butyl 1,3-thiazole-2-yl-carbamate 

Downstream Products

• 881402-27-3 tert-butyl (5-bromothiazol-2-yl)(4-methoxybenzyl)carbamate 
• 731018-54-5 2-(tert-butoxycarbonyl)amino-5-fluorothiazole 
• 957147-21-6 (5-trimethylsilanylethynyl-thiazol-2-yl)-carbamic acid tert-butyl ester 
• 944804-72-2 (S)-tert-butyl 1-(N-(5-bromothiazol-2-yl)-tert-butoxycarbonylamino)-3-(4-(trifluoromethyl)phenyl)propan-2-ylcarbamate 
• 1355249-33-0 C₂₁H₂₆N₄O₅S 
• 1355249-32-9 C₂₅H₃₀N₄O₇S 
• 944805-17-8 tert-butyl (4-bromo-5-formylthiazol-2-yl)carbamate 
• 1245647-27-1 (5-Vinyl-thiazol-2-yl)-carbamic acid tert-butyl ester 
• 1236031-10-9 tert-butyl (5-bromo-1,3-thiazol-2-yl)((2R,3S)-2-((tert-butoxycarbonyl)amino)-3-((tert-butyl(dimethyl)silyl)oxy)-3-(4-(1,1-difluoroethyl)phenyl)propyl)carbamate 
• 1236030-15-1 1,1-dimethylethyl 5-bromo-1,3-thiazol-2-yl((2S)-3-(4-(1,1-difluoroethyl)phenyl)-2-((((1,1-dimethylethyl)oxy)carbonyl)amino)propyl)carbamate 
• 1236031-15-4 tert-butyl (5-bromo-1,3-thiazol-2-yl)((2R,3S)-2-((tert-butoxycarbonyl)amino)-3-((tert-butyl(dimethyl)silyl)oxy)-3-(4-(trifluoromethyl)phenyl)propyl)carbamate 
• 1081314-08-0 tert-butyl-{5-[hydroxy(3-trifluoromethylphenyl)methyl]thiazol-2-yl}carbamate 
• 944804-88-0 tert-butyl N-(4-bromo-1,3-thiazol-2-yl)carbamate 
• 405939-42-6 [6-(2-{tert-butoxycarbonyl-[3-(tert-butyl-dimethyl-silanyloxy)-propyl]-amino}-thiazol-5-yl)-pyrazin-2-yl]-(3-chloro-phenyl)-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Halogen-Dance-Based Synthesis of Phosphonomethoxyethyl (PME) Substituted 2-Aminothiazoles as Potent Inhibitors of Bacterial Adenylate Cyclases

A series of acyclic nucleoside phosphonates (ANPs) was designed as inhibitors of bacterial adenylate cyclases (ACs), where adenine was replaced with 2-amino-4-arylthiazoles. The target compounds were prepared using the halogen dance reaction. Final AC inh

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.

NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9

The present invention relates to an inhibitor of cyclin-dependent kinase CDK9, having a structure of formula (I). The present invention also provides a method of treating a cancer of a precancerous condition related to CDK9 activity with the inhibitor and a use of the same.

DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF

Diazanaphthalene compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a diazanaphthalene compound or analogs thereof, in the treatment of disorders characterized by the activa

SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES

The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3, R4, R5, R6 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS

The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other -threonine kinase mediated diseases, having the Formula: (I) wherein A, L, R1, R2, R3, and n are described herein.

Preparation of 3,4-Substituted-5-Aminopyrazoles and 4-Substituted-2-Aminothiazoles

3,4-Substituted-5-aminopyrazoles and 4-substituted-2-aminothiazoles are frequently used intermediates in medicinal chemistry and drug discovery projects. We report an expedient flexible synthesis of 3,4-substituted-5-aminopyrazoles (35 examples), based on palladium-mediated α-arylation of β-ketonitriles with aryl bromides. A library of 4-substituted-2-aminothiazoles (21 examples) was assembled by a sequence employing Suzuki coupling of newly prepared, properly protected pinacol ester and MIDA ester of 4-boronic acid-2-aminothiazole with (hetero)aryl halides.

Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor

Through a structure-guided rational drug design approach, we have discovered a highly selective inhibitor compound 40 (JSH-150), which exhibited an IC50 of 1 nM against CDK9 kinase in the biochemical assay and achieved around 300–10000-fold selectivity over other CDK kinase family members. In addition, it also displayed high selectivity over other 468 kinases/mutants (KINOMEscan S score(1) = 0.01). Compound 40 displayed potent antiproliferative effects against melanoma, neuroblastoma, hepatoma, colon cancer, lung cancer as well as leukemia cell lines. It could dose-dependently inhibit the phosphorylation of RNA Pol II, suppress the expression of MCL-1 and c-Myc, arrest the cell cycle and induce the apoptosis in the leukemia cells. In the MV4-11 cell-inoculated xenograft mouse model, 10 mg/kg dosage of 40 could almost completely suppress the tumor progression. The high selectivity and good in vivo PK/PD profile suggested that 40 would be a good pharmacological tool to study CDK9-mediated physiology and pathology as well as a potential drug candidate for leukemia and other cancers.

CYANOPYRROLIDINE DERVIVATIVES AS INHIBITORS FOR DUBS

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of Cezanne 1 and ubiquitin C-terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of cancer. Compounds of the invention include compounds having the formula (I): pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f and A are as defined herein.